
Pamela Kunz, MD, FASCO
@pamelakunzmd
Div Chief GI Onc @YaleCancer | #NETs
Editor-in-Chief, JCO OA @JCO_ASCO | ASCO FCOI: bit.ly/3IPTmtk
Public Voices Fellow of @TheOpEdProject
ID: 2980465697
https://medicine.yale.edu/profile/pamela_kunz/ 15-01-2015 22:08:34
4,4K Tweet
8,8K Followers
4,4K Following




🔥🚨HOT OFF THE PRESS Just published Journal of Clinical Oncology IMPORTANT SPECIAL ARTICLE & #Recommendations for #Academic #MedicalCenters by ASCO on: Promoting Reasonable #CareerExpectations & Maximizing Professional Fulfillment for #Academic #Oncologists PLZ SHARE👇🏻 ascopubs.org/doi/10.1200/JC…


Standing room only for an outstanding presidential address by Callisia Clarke MD “Hidden Figures: They are all around us”Assoc4AcademicSurgery #ASC2025 #ASC25 #SurgTwitter #Academic #Surgery





Amazing symposium today UPMC Hillman Cancer Center hosted by the Women's Initiative Taskforce on "Bridging the Gap." It's been my pleasure to participate. 🙏

Congratulations to the Center for Gastrointestinal Cancers team and Michael Cecchini for enrolling the 1st patient in the US in the OrigAMI-2 trial for unresectable or metastatic left-sided colorectal cancer. Learn more about the study: medicine.yale.edu/ycci/clinicalt… #CRC #CRCSM Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp


It was such an honor to be the Keynote speaker along with Pamela Kunz, MD, FASCO in the UPMC Hillman Cancer Center Women’s Initiatives Taskforce Symposium. An incredible day of science and inspiration. Organizers 💪🏼 Overacre Lab Dr Kathryn Schmitz, Michelle Williams, Tullia Bruno, PhD Olja Finn, Annie Im.




Thank you to Dr. Douglas Evans Medical College of Wisconsin for presenting #GrandRounds + #Schnog Lecture discussing important advances in pretreatment staging, therapy, and palliative care for #pancreaticcancer. Watch his talk now youtube.com/watch?v=7oXlcS…. Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp


COMPETE trial results are out! Presented by Jaume Capdevila Lu177-edo vs Everolimus in G1/2 GEPNETs either 1st line or after progression on SSA (mostly second line). PFS favors PRRT (HR=0.67), interim OS numerically favors PRRT, safety favors PRRT. First phase 3 trial



#ASCO25 ASCO 4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍 👇my top picks for key abstracts to watch for🌟 ➡️Two GI plenary sessions🏅 MATTERHORN #STCsm Yelena Y. Janjigian MD ATOMIC #dMMR #CRCsm Frank Sinicrope, MD ➡️Clinical Science Symposium


Thrilled to share our latest Review on Gastric Cancer in the The Lancet covering the latest in the treatment and management of this illness Lizzy Smyth Kohei shitara Hanneke van Laarhoven Sheraz Markar Yelena Y. Janjigian MD & Izuma Nakayama. thelancet.com/journals/lance…
